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110a Sunday, February 8, 2015in addition to its significantly higher S/B ratio. It requires minimal amount of
organic-anion transporter inhibitor (such as probenecid) in its assay system.
In conclusion, Cal-590 AM is a greatly improved red fluorescent indicator
for measuring intracellular calcium change. The red-shifted wavelength makes
Cal-590 AM a robust tool for evaluating GPCR and calcium channel targets,
multiplexing analysis of cellular functions with a green fluorescent dye as
well as screening agonists and antagonists with GFP cells.
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The STIM-Orai activating region (SOAR) of STIM1 is the minimal sequence
necessary for Orai1 channel activation. Our previous work revealed that
replacement of Phe-394 in SOAR with the dimensionally similar but polar his-
tidine head group prevents Orai1 binding and gating. In the current study, we
constructed YFP-SOAR-SOAR concatemers with a 21 amino acid linker
between the SOAR units which allowed folding into functional dimers. We
introduced the F394H mutation (FH) into either the first (N-terminal) or second
(C-terminal) SOAR unit within the dimeric concatemer constructs. We found
that each of these single-mutated concatemers was able to both bind to Orai1
and gate the Orai1 channel normally, the same as the wild-type concatemer.
In contrast, a concatemer in which both SOAR units contained the F394H
mutation (YFP-SOARFH-SOARFH), was devoid of Orai1 binding and gating
activity. To ensure that the single mutated concatemers were not forming
inter-concatemer dimers, we equally co-expressed the CFP-SOARWT-
SOARWT and YFP-SOARFH-SOARFH concatemeric constructs in the same
cell. While the CFP-SOARWT-SOARWT bound to and activated Orai1, it did
not pull the YFP-SOARFH-SOARFH with it. Thus, the latter remained in the
cytosol in these cells. This result is in contrast to co-expression of the mono-
meric CFP-SOARWT with YFP-SOARFH constructs. In this case, while the
YFP-SOARFH expressed alone does not bind to or activate Orai1, the CFP-
SOARWT clearly dimerizes with YFP-SOARFHmutant and pulls it to the PM.
This also proves that he F394H mutation does not prevent SOAR-SOAR dimer
formation. Overall, the results reveal a surprising new facet of the STIM1-
Orai1 coupling interaction. Thus, although the SOAR dimer is likely the func-
tional Orai1-actiavting unit, only one of the SOAR units within the SOAR
dimer needs to be able bind to and activate the Orai1 channel.
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Receptor-stimulated Ca2þ influx, a critical component of the Ca2þ signal, is
mediated in part by Orai1, which is activated by STIM1 in response to Ca2þ
release from the ER. Orai1 then undergoes slow Ca2þ-dependent inactivation
(SCDI) that is mediated by binding of SARAF to STIM1. We use SCDI by
SARAF as reporter of the conformation and microdomain localization of the
Orai1-STIM1 complex. Interaction of STIM1 with the C terminus of Orai1
and the STIM1 K-domain are required for interaction of SARAF with
STIM1 and Orai1 SCDI. Interaction of SARAF with STIM1 required the pres-
ence of STIM1-Orai1 in a PM/ER microdomain that is tethered by E-Syt1, sta-
bilized by Septin4 and enriched in PI(4,5)P2. Notably, selective targeting of
STIM1 to PI(4,5)P2-rich or to PI(4,5)P2-poor microdomains revealed that
SCDI by SARAF is observed only when the STIM1-Orai1 complex is within
the PI(4,5)P2-rich microdomain. Most notably, measuring the dynamics of
STIM1-Orai1 complex localization in live cells using PI(4,5)P2-rich or
PI(4,5)P2-poor microdomain probes revealed that store depletion is followed
by transient STIM1-Orai1 complex formation in the PI(4,5)P2-poor microdo-
main where the channel is fully active, which then translocates to the PI(4,5)
P2-rich domain to recruit SARAF and initiates SCDI. These findings reveal
the role of the PM/ER tethers in the regulation of Orai1 function and Ca2þ
influx and describe a new mode of regulation by PI(4,5)P2 involving transloca-
tion between PI(4,5)P2 microdomains, rather than by PI(4,5)P2 synthesis and
breakdown.Cardiac Smooth and Skeletal Muscle
Electrophysiology I
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Atrial fibrillation (AF) contributes significantly to cardiovascular morbidity and
mortality. The growing epidemic is associated with cardiac repolarization abnor-
malities and requires the development ofmore effectiveantiarrhythmic strategies.
Cardiac two-pore-domain Kþ channels repolarize action potentials and represent
potential targets for AF therapy. However, electropharmacology ofK2P channels
remains to be investigated in detail. This study was designed to elucidate human
K2P channel regulation by antiarrhythmic drugs vernakalant and flecainde.
Two-electrode voltage clamp and whole-cell patch clamp electrophysiology
was used to record K2P currents from Xenopus oocytes and Chinese hamster
ovary (CHO) cells. The class III antiarrhythmic compound vernakalant acti-
vated K2P17.1 currents in oocytes and in mammalian cells (EC50,CHO ¼
40 mM) in frequency-dependent fashion. K2P17.1 open rectification character-
istics and current-voltage relationships were not affected by vernakalant. In
contrast to K2P17.1, vernakalant reduced K2P4.1 and K2P10.1 currents, in
line with K2P2.1 blockade reported earlier. The class I drug flecainide did
not significantly modulate K2P currents.
In conclusion, vernakalant activates K2P17.1 background potassium channels.
Pharmacologic K2P channel activation may be employed for personalized
rhythm control in patients with AF-associated reduction of Kþ channel function.
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The emergence of human induced pluripotent stem (hiPS) cell technology has
expanded the possibilities for sourcing human cardiomyocytes (hiPS-CMs).
Novel microscopy and analysis methods serve to accelerate development and
validation of in vitro hiPS-CM models for drug screening. Voltage sensitive
dyes (VSD) allow non-invasive, non-destructive, and longitudinal assessment
of hiPS-CM electrophysiology at the sub-cellular membrane scale. In this
study, we successfully use 2-photon microscopy to capture VSD signal at the
cellular membrane scale generated from actively beating hiPS-CMs exposed
to the chronotropic drugs, propranolol (105 M) and isoproterenol (107 M).
We use SimFCS software, developed at the Laboratory for Fluorescence Dy-
namics at the University of California, Irvine, to remove motion artifact and
assess the resultant signal over time. We are able to generate a waveform of
VSD fluorescence that is representative of the changing membrane potential
(i.e. the depolarization of an action potential). A number of characteristics of
these waveforms are defined (upslope, maximum height, plateau height, down-
slope, peak width, and beat rate), compared across treatments, and shown to be
significantly different between treatments. A supervised machine learning algo-
rithm is then trained, validated, and the algorithm accuracy quantified using
these data along with their known drug treatments. The algorithm that results
can be used to predict which drugs hiPS-CMs have been exposed to given
only their respective VSD waveforms. This study tests the hypothesis that
VSDs may be used in conjunction with supervised learning to train an algo-
rithm that is capable of automatically and accurately assessing, classifying,
and predicting the membrane depolarization effects of chronotropic drugs.
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Introduction: The proarrhythmic effects of quinolone antibiotics used clini-
cally have been assessed by measuring the IKr antagonist potency. However,
the gaps between clinically reported proarrhythmic effects and IKr antagonist
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arrhythmogenic effects of one quinolone antibiotic, sparfloxacin (SPX).
Methods andResults: In thepresent study,we investigated possible involvement
of ICaL in the SPX-induced APD prolongation in neonatal rat ventricular myo-
cytes using patch clamp technique. In the presence of IKr blocker, E4031, APD
prolongation was evident perfused with sparfloxacin at 3  104 M and stimu-
lated at 2 Hz, indicating the involvement of additional channel in SPX-induced
proarrhythmic properties. The APD prolongation was associated with a slowing
of inactivation of ICaL. In contrast to SPX, four other quinolones including cipro-
floxacin, enoxacin, ofloxacin, and levofloxacin, which are not related to VT, did
not affect ICaL. Sparfloxacin increased the inactivation time constants of ICaL in a
concentration-dependent manner, resulting larger steady-state currents. Further
analysis showed that sparfloxacin reduced Ca2þ-dependent component of
steady-state inactivation. Consistent with modulation of Ca2þ-dependent inacti-
vation (CDI) by sparfloxacin, replacement of extracellular Ca2þwith Ba2þ abol-
ished sparfloxacin action on ICaL inactivation. Use-dependency wasmeasured by
applying repetitive voltage pulses at 2 Hz.We found that sparfloxacinmodulated
Ca2þ-dependent inactivation of ICaL in a use-dependent way.
Conclusion: The present findings demonstrate the role of ICaLin SPX-induced
APD prolongation. We further provide the evidence that SPX modified the
shape of ICaL by altering kinetics of Ca
2þ-dependent inactivation (APD).
This study suggests that quinolones causing delay of ICaL inactivation com-
bined with IKr block may have more adverse effects than those with purely se-
lective IKr block.
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Lethal arrhythmia is one of themajor safety concerns for developing drug candi-
date compounds, nevertheless, conventional cardiotoxicity prediction methods
like in vitro hERG/APD and in vivo QT assay cannot be eliminated the false
negative/positive problem. To overcome this problem, we have developed an
on-chip new in vitro predictive cardiotoxicity assay having a quality of clinical
screening using constructive human cardiomyocyte networks derived from hu-
man stem cells (hES-CMs) employing a spatiotemporal measurement of fluctu-
ation (short-termvariability; STV) of temporal repolarization of cells and spatial
cell-to-cell conduction, representing two origins of lethal arrhythmia. First, we
examined the electrophysiological prolongation of field potential durations
(FPDs) of human cardiomyocytes to compare the conventional in vivo QT pro-
longation and clinical results. The results showed (1) FPD prolongation has the
ability to detect QT/pro-arrhythmic risks almost similar to the conventional
in vitro APD measurements such as papillary muscle and Langendorff hearts.
However, they did not show significant improvement of the false-positive/
negative problems. Then we evaluated the new two spatiotemporal fluctuations,
and found that (2) temporal fluctuations of FPDs (STVFPD) predicted ventricular
arrhythmia risks more precisely in most of the representative compounds
including false-positive/negative compounds except for terfenadine, and that
(3) even the risk of those false-negative drugs including terfenadine was pre-
dicted by the fluctuation of spatial cell-to-cell conduction in the lined-up cardi-
omyocyte network. In conclusion, only the replacement of animal cells to human
cardiomyocytes in conventional in vitro screening is not enough to get precise
prediction, whereas, the combination of human cardiomyocytes with the new
approach of two spatiotemporal fluctuation measurements of temporal STVFPD
and spatial STVConductance gives us an potential of global precise predictive
arrhythmic cardiotoxicity as a quasi-in vivo human cell network screening
beyond conventional hERG and APD/QT assays.
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A new trend in the industry utilizes induced pluripotent stem cells (iPSCs) for
functional assays to identify cardiac pathologies and their genetic underpin-
nings (such as Long QT Syndrome (LQTS)), in addition to cardiotoxicity
profiling of pharmaceutical compounds.
The here utilized CardioExcyte 96 system is a hybrid instrument that com-
bines impedance readout (a correlate of cell contractility) with electric field po-
tential recordings of the compound signal that is generated by cellular action
potentials. These electrophysiological measurements are label-free and allowinvestigations in High Throughput format. In addition, the instrument is
capable of electrical stimulation of the cellular monolayer, while the rapid
acquisition rate of 1ms allows a more accurate description of signal features
and nuances stemming from pharmacological effects. A dedicated software
package for rapid data handling and real-time analysis is based on novel algo-
rithms that allow a comprehensive investigation of the cellular beat signal.
A broad range of cell lines was successfully validated, such as stem cell-derived
cardiomyocytes from Axiogenesis (human: Cor4U, murine: CorAt), GE
Healthcare (Cytiva), Cellectis (human, 3D-clusters: hES-CMC) and CDI
(iCell). Furthermore, the pharmacological effects of a number of reference
compounds on these cell typeswere evaluated and their phenotype correctly iden-
tified. For example, the effects of compounds like Blebbistatin, which blocks
contraction without disrupting the electric field potential can be easily identified
since it is an inhibitor of themyosin IIwhich ismainly responsible for the contrac-
tion of cardiomyocytes,while it has noeffect to the ionchannels.Other compound
classes like hERG inhibitors were validated as well and example data will be
shown. They induce typical arrhythmia since hERG ion channels are affected.
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Many drugs, both cardiac and non-cardiac, cause fatal arrhythmias. Current as-
says to evaluate arrhythmia risk based on block of the delayed rectifier Kþ cur-
rent (hERG) and QT interval prolongation are limited by poor specificity. We
hypothesize that physiological, dynamical simulations of drug effects on heart
cells will yield better algorithms to discriminate between arrhythmogenic and
safe drugs. To test this, we model drug action in cardiomyocyte models based
on drug interactionwith 3 cardiac ion channels: hERG, the L-type Ca2þ channel,
and the fast Naþ channel. For 67 distinct drugs, we measure 15 cellular physi-
ological metrics under multiple pacing conditions and in the 3 ventricular cell
types, each in 3 human ventricular cell models. Additionally, we evaluate the
influences of gender and inter-individual variability on risk by conducting sim-
ulations in both female and male models, and in a simulated population of indi-
viduals, respectively. Principal component analysis of these drug effect metrics
reveals distinct behaviors of arrhythmogenic drugs. This segregation of drugs in
principal component space facilitates their classification into arrhythmogenic
and safe categories. Our classification by this method is more sensitive and spe-
cific than the hERG block assay or, to our knowledge, any other published pre-
dictors, with an area under the receiver-operator characteristic of 0.9630.
Furthermore, because it is based on cellular physiologicalmetrics, our algorithm
can predict the arrhythmogenicity of drugswith a range of cardiacmolecular tar-
gets, beyond those of the drugs used to train the algorithm. In conclusion, we
have developed a classification algorithm using dynamical heart cell models,
suitable for cardiac safety assessments early in drug development, that outper-
forms current methods in the discrimination of arrhythmogenic and safe drugs.
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Introduction: Cardiac tissue slices, a pseudo two-dimensional organo-typic
experimental model, are an increasingly popular model to study cardiac
biophysics in-vitro. This preparation benefits from moderate complexity, native
cell-type presence, and locally preserved cell-cell connections. We used optical
mapping of tissue slices to monitor transmembrane potential (Vm) and intracel-
lularCa2þ concentration to study the effects of stretch onactionpotential duration
(APD) and calcium transient (CaT) dynamics with a relatively high spatio-
temporal resolution, to explore mechanisms of stretch-induced arrhythmias.
Methods: Langendorff perfused rabbit hearts were loaded with dyes for Vm
(di-4-ANBDQPQ) and CaT (Rhod-2-AM). Thereafter, 350 mm tissue slices
were vibratome-cut from left and right ventricular free wall in an
epicardium-tangential plane. Slices were attached at their ends to a manual
stretcher and optically mapped using an EMCCD camera with LED excitation
light sources. Slices were field stimulated at 2Hz, and Vm and CaT were
measured before, during (up to 50min) and after application of stretch.
Results: Cardiac tissue slices (n¼9), exposed to stretch (by 4-12%) showed an
initial shortening in both APD and CaT duration (APD80 and APD50 reduced
